Before treatment: Botox: What Does It Do and Who Can Get It?

Before Botox

What is Botox, and what does Botox do?

Botox Cosmetic temporarily improves specified expression lines by blocking nerve signals to treated muscles, according to the American Society of Plastic Surgeons and the FDA label revised October 2024. Its adult cosmetic indications name four concerns, including platysma bands. Botox is a brand, while botulinum toxin is the drug family.

The distinction matters at your first appointment. Forehead lines involve the frontalis muscle, frown lines involve the corrugator and procerus, and crow’s feet involve orbicularis oculi. The drawing connects those muscles with the concerns named in the label. ASPS describes a thin needle delivering toxin into selected muscles and says planning depends on facial features and wrinkle extent. Cleveland Clinic distinguishes toxin, which relaxes muscles, from filler, which adds volume. The prescription products Botox and Botox Cosmetic share an active ingredient and formulation but have different labeled indications. You can discuss a concern without committing to treatment. Bring a clear description of the expression or line you want changed and the movement you want to retain. The sources do not supply a dose that produces the same expression in every face.

Before Botox

Where is Botox FDA approved for cosmetic use?

Botox Cosmetic has four adult cosmetic indications in its October 2024 FDA label, while the other five US-approved cosmetic neurotoxins have their own area limits in the labels checked October 17, 2026. Approval belongs to a specific product, indication and regimen. An approval for one brand does not transfer to another.

The comparison below names moderate to severe lines because that is the severity in the accessed indications. The active ingredients are onabotulinumtoxinA in Botox Cosmetic, abobotulinumtoxinA in Dysport, incobotulinumtoxinA in Xeomin, prabotulinumtoxinA-xvfs in Jeuveau, daxibotulinumtoxinA-lanm in Daxxify and letibotulinumtoxinA-wlbg in Letybo. These are botulinum toxin type A products. Glabellar means the frown-line area between the eyebrows. Lateral canthal means crow’s feet at the outside of the eyes. Xeomin’s accessed cosmetic label includes glabellar, horizontal forehead and lateral canthal lines in adults. Dysport’s cosmetic indication is moderate to severe glabellar lines in adults younger than 65. Jeuveau, Daxxify and Letybo each have an adult glabellar-line cosmetic indication in the accessed labels. Daxxify’s separate cervical-dystonia indication is a medical use, not cosmetic approval for neck shaping. Botox Cosmetic’s platysma-band indication is specific to moderate to severe bands associated with platysma muscle activity in adults. It does not make every jawline technique, loose-skin treatment or injection anywhere on the neck labeled. If a product is proposed outside its indication, ask for that to be identified in the consent discussion before any injection.

Before Botox

How many units of Botox are used per area?

The October 2024 Botox Cosmetic label specifies 20 Units for glabellar lines, 24 Units total for crow’s feet, and 40 Units for forehead plus glabellar treatment. Those 40 Units include 20 in the forehead and 20 in the glabella. They are labeled regimens, not a personal dose recommendation.

ASPS says facial features and wrinkle extent inform planning. The Botox Cosmetic label instructs treating forehead lines with glabellar lines to minimize brow-ptosis potential. A quotation for forehead treatment needs to say whether the glabella is included. Do not read forty units as forty units placed only in the forehead. For labeled platysma treatment, Botox Cosmetic gives totals of 26 Units for one band on each side, 31 Units when one side has one band and the other has two, and 36 Units for two bands on each side. These totals include the upper-platysma sites below the jawline as well as the vertical bands. The drawing keeps product-specific regimens separate. A unit is a biological potency measure for its own product; it is not a needle puncture, milliliter, syringe or universally comparable amount. A clinic charging per area still needs to identify the product and actual units in the record.

Before Botox

Is Botox the same as Dysport or other neurotoxins?

Botox and Dysport are different prescription products with units that cannot be converted using a universal label-approved ratio, according to their FDA prescribing information checked October 17, 2026. The same product-specific restriction applies to Xeomin, Jeuveau, Daxxify and Letybo. A larger unit number does not by itself mean stronger treatment.

For glabellar lines, Dysport’s labeled total is 50 Dysport Units, while Daxxify’s is 40 Daxxify Units. Jeuveau and Letybo each list 20 of their own Units. Xeomin lists a maximum of 20 Units for glabellar lines and a maximum combined 40 for horizontal forehead with glabellar lines. Its lateral-canthal total is 24, with a maximum of 64 for simultaneous treatment of all three upper-face areas. Those numbers describe separate labels. They do not form a conversion chart or a ranking of effect, value or safety. The labels use their own assays and product wording; the exact unit-language excerpts are kept in the figure. If you previously had another brand, bring the product name, area, date and dose from the actual treatment record. Ask before consenting to a substitution. Product price, onset, duration and preferred expression can all enter a conversation, but separate registration trials cannot determine the brand that will suit you. The cost guide keeps each product’s unit scale and billing scope separate for the same reason.

Before Botox

Are masseter Botox, a lip flip and neck Botox off-label?

Masseter slimming and a lip flip are off-label cosmetic neurotoxin uses in the six product labels checked October 17, 2026, while Botox Cosmetic has a labeled platysma-band indication in its October 2024 label. Neck treatment must be identified product by product. Neck-band treatment with Dysport, Xeomin, Jeuveau, Daxxify or Letybo is off-label under the accessed cosmetic labels.

A lip flip aims to change upper-lip position through muscle effects; it is different from adding volume with filler. Gummy-smile treatment is another off-label purpose, not a synonym for either treatment. The lower face involves expression and mouth function, so ask about drinking, speaking and smiling as well as photographs. The supplied evidence does not establish a US population rate for unwanted oral-function changes after a lip flip or a personal masseter dose. Masseter slimming is off-label even when the clinic calls the appointment jawline contouring. For the neck, distinguish visible platysma bands from loose skin, fat and a desired jawline change. Botox Cosmetic’s labeled regimen includes specific sites below the jawline, but that fact does not approve every contouring technique. The 2026 platysma review in the packet includes three randomized trials and 912 participants and compares onabotulinumtoxinA with placebo. It does not compare toxin with a surgical neck lift or establish that they offer the same change. Use the existing lower-face article for the wider discussion rather than assuming all lower-face concerns fit this guide. An off-label discussion should identify the purpose, evidence, limitations and specific consent before treatment.

Go deeperLower-face Botox and off-label scope Nefertiti neck treatment context

Before Botox

Does baby Botox prevent wrinkles?

Preventative Botox for future wrinkles is off-label in the six cosmetic labels checked October 17, 2026, and “baby Botox” is an undefined marketing term rather than an FDA indication. None of those six labels establishes future-wrinkle prevention. Ask what actual indication, dose and technique the term describes.

The word baby can mean different things in different advertisements. It cannot tell you whether a proposed treatment follows a label. A reduced-dose, superficial or other modified regimen marketed as baby Botox should be discussed as off-label when it departs from that product’s indication or dosing and technique. The corrected research specifically warns against classifying every use of the phrase as off-label without knowing the actual treatment. Equally, the phrase cannot serve as evidence of an approved preventive treatment. Existing-line trials measure changes in present wrinkles at specified assessments. They cannot establish that a younger person needs injections now to prevent aging later. ASPS describes effects as temporary and says muscle reactions and wrinkles return as effects fade. That supports discussing repeat treatment as a choice; it does not establish that starting obliges you to continue or that stopping accelerates aging. You can decide that a temporary change, its risks and repeat expense do not match your priorities.

Safety and choosing care

Who should not get Botox or another neurotoxin?

Botox Cosmetic is contraindicated for hypersensitivity to any botulinum toxin preparation or formulation component and infection at the injection site, according to its October 2024 label. The other five products have their own contraindication wording, reproduced below. Dysport additionally names cow’s milk protein hypersensitivity.

Contraindication has a specific meaning in prescribing information. It should not be replaced by a general list of concerns from a clinic advertisement, and a warning should not silently become a formal contraindication. Tell the clinician what product caused a previous reaction, what happened and what treatment you needed. Do not assume a different brand avoids the problem. Each label’s component language matters, and a milk-protein allergy must not be transferred to products with different formulations. The six product cards retain the accessed highlights wording, with typography normalized for reading. The label links lead to the complete prescribing information, which supplies context beyond these excerpts. An intended injection site that is infected needs clinical assessment before proceeding. The labels also discuss serious hypersensitivity reactions and other precautions that require the prescriber’s judgment. Ask the clinician to review the exact product they plan to administer rather than a generic Botox consent sheet that never identifies it.

Safety and choosing care

Can I get Botox while pregnant or taking medicines?

Botox Cosmetic’s October 2024 label lacks adequate human developmental-risk data in pregnancy and milk or breastfed-child data, while Mayo Clinic says providers generally do not recommend Botox during pregnancy or breastfeeding. Pregnancy is not in that label’s formal contraindication list. The other five product labels also describe absent or inadequate human data.

Absence of adequate data does not establish safety. Discuss pregnancy, plans for pregnancy and breastfeeding before booking, and ask how the clinician applies the specific product information to your situation. The Botox Cosmetic label warns that pre-existing neuromuscular disorders can increase clinically significant effects. That warning needs to stay distinct from its formal contraindications. All six product labels identify potential interactions with aminoglycosides or other medicines affecting neuromuscular transmission. Tell the clinician about prescriptions, over-the-counter pain relievers, muscle relaxants, supplements and vitamins; ASPS and AAD support reviewing this full history. Bring the actual medication names and recent treatment dates rather than assuming a product sold without a prescription is irrelevant. Mayo says blood-thinner changes should be discussed with the prescribing provider. Do not stop a prescribed anticoagulant to follow an online bruising tip. A previous operation or cosmetic treatment may also matter to anatomy and the plan, as AAD notes.

Safety and choosing care

What is the Botox boxed warning about distant spread?

Botox Cosmetic and the other five cosmetic neurotoxins carry a boxed warning titled “WARNING: DISTANT SPREAD OF TOXIN EFFECT,” and the accessed labels say symptoms have been reported hours to weeks after injection. Their warnings include potentially life-threatening swallowing and breathing difficulties and reports of death. Seek immediate medical attention for respiratory, speech or swallowing difficulties, as the product labeling instructs.

The figure preserves each product’s accessed boxed-warning highlights text rather than replacing it with a claim that serious spread is impossible at cosmetic doses. The full prescribing information adds context; the highlights themselves direct readers there. It covers reported events and susceptible populations, and its mention of children treated for spasticity is not an indication for pediatric cosmetic treatment. This guide concerns adults. CDC describes botulism as a medical emergency and says not to wait for help when symptoms appear. Blurry or double vision, eyelid droop, muscle weakness and swallowing or breathing difficulty after injections need prompt medical assessment. Contact the treating clinician right away for a new concern; do not let a reassuring forum reply delay immediate care for breathing, speech or swallowing difficulty. The warnings do not imply that every heavy-feeling brow is distant spread, but a webpage cannot diagnose the cause. Tell the assessing team the product, date, dose and treatment setting if available.

Safety and choosing care

What are Botox side effects and how common are they?

Botox side effects depend on the area and regimen; its October 2024 label reports eyelid ptosis in 13 of 405 glabellar recipients, 3%, versus none of 130 placebo recipients. In separate forehead-plus-glabellar trials, headache occurred in 58 of 665 treated participants, 9%, versus 17 of 315 placebo participants, 5%. These are trial observations, not a personal prediction.

Ptosis means drooping. Eyelid ptosis and brow ptosis are different findings and should not be combined into one risk number. In those forehead-plus-glabellar Botox Cosmetic trials, eyelid ptosis was 12 of 665, 2%, versus 1 of 315 placebo recipients, rounded to 0% in the label; brow ptosis was 13 of 665, 2%, versus none of 315. The figure includes other products with their own populations. Xeomin’s upper-face trial table reports injection-site bruising in 2% of 545 active recipients versus 1% of 185 placebo recipients. These are reported percentages, so we do not manufacture event counts. A repeated-dose Xeomin population of 720 subjects has a different follow-up and cannot be added to the first-cycle table. Daxxify’s injection-site reaction category combines pain, redness, swelling, bruising and other reactions, so its 6% is not a standalone bruising rate. Each label cautions that trial rates cannot be directly compared with another drug’s trials. The tables therefore do not rank products. Ask the treating clinician promptly about new eyelid droop, visual changes or an unexpected symptom; immediate medical attention is needed for respiratory, speech or swallowing difficulties. ASPS also lists bruising, pain, redness and temporary facial weakness, without a universal numerical rate.

Safety and choosing care

Can Botox stop working because of antibodies?

Botox Cosmetic antibody testing found binding antibodies in 14 of 916 tested lateral-canthal study subjects, 1.5%, and no developed neutralizing antibodies, according to its October 2024 label. Binding antibodies and clinically meaningful resistance are different findings. A short or disappointing result alone cannot diagnose antibody-mediated nonresponse.

The denominator here is the group tested, not every person ever treated with Botox Cosmetic. Other labels use different analysis populations, assays and follow-up. Dysport reports no neutralizing antibodies among 1,554 tested glabellar subjects with up to nine cycles. Jeuveau reports two subjects with pre-existing antibodies and two with treatment-emergent antibodies among 1,414 treated subjects, without labeling those findings as proven clinical resistance. Daxxify’s label analysis includes 2,786 subjects, with 0.8% anti-toxin antibodies and 1.2% anti-peptide antibodies over up to three treatments and 120 weeks; anti-peptide findings are not toxin-neutralizing antibodies. Letybo reports four of 1,195 treated subjects, 0.3%, with anti-drug antibodies; selected positive samples tested further had no neutralizing antibodies. No zero in these finite studies establishes a zero lifetime possibility. The labels explain that antibody incidence depends on assay sensitivity and specificity. Do not use different percentages to rank brands or choose a rotation schedule. Bring the actual product, area, dose, date and observed course to the clinician. The Botox Cosmetic label says determinants of neutralizing antibodies are poorly characterized and notes an association in some studies with higher doses or more frequent treatment. It does not supply a do-it-yourself rescue protocol.

Safety and choosing care

How long does Botox last, and when does Botox work?

Botox effects usually begin in one to three days and full effects may take a week or more, according to Mayo Clinic guidance checked October 17, 2026; its general duration estimate is three to four months. Those are broad Botox estimates. Product labels and studies use distinct onset and duration endpoints.

The drawing keeps Dysport’s label description of reduced glabellar severity for up to four months separate from Xeomin’s median onset within two to seven days and typical effect up to 12–16 weeks. A first noticed change, a full effect, movement returning and a return to baseline line severity are different milestones. The 2012 Glogau meta-analysis in the packet conditions its Botox glabellar duration estimate on day-30 responders across four trials. That selection cannot describe every person who receives treatment. Likewise, a study median for another product cannot establish the date you will need another appointment. ASPS says movement and wrinkles return as the effect fades. Discuss whether that gradual return would bother you enough to repeat treatment and how you would budget if you chose to continue. The Botox Cosmetic label says dosing more often than every three months has not been clinically evaluated; the other products have their own retreatment language. An event deadline is not a reason to assume an early extra dose is appropriate. If this is your first treatment before a wedding or trip, ask how follow-up and a possible unwanted effect would be handled. The packet does not establish one universally safe event interval.

Safety and choosing care

Who can legally inject Botox in Utah?

Utah permits authorized RN performance of covered nonablative cosmetic medical procedures, including cosmetic Botox injection, under general cosmetic medical supervision, subject to scope and training, under Section 58-1-506 checked October 17, 2026. The statute requires a qualifying practitioner’s plan and evaluation before the treatment series. An injection-course certificate alone does not establish authority.

Utah’s definition includes cosmetic injection of a medication or substance, including a neurotoxin or filler. Section 58-1-506 says cosmetic medical procedures may only be performed in a cosmetic medical facility. For a nonablative procedure other than hair removal, its initial plan-and-evaluation provision names an unrestricted physician, nurse practitioner or physician assistant acting under the specified statutory authority. The evaluation may be in person or by live telemedicine before the treatment series. The statute’s general-supervision framework includes being within 60 minutes or 60 miles of the facility. Ask who actually evaluates you, writes the plan and is available at that appointment. The covered provisions require written supervisor and performer licensing information and a follow-up phone number answered within 24 hours. The reenacted nursing statute gives APRNs prescribing or administration authority within its framework; RN administration does not become independent prescribing. The master-esthetics provisions do not create a freestanding neurotoxin-injection license. Some related Utah rule text in the packet was available only through mirrors; this chapter relies on the official statutory provisions and does not claim that an inaccessible rule was independently confirmed current.

Safety and choosing care

Who can inject Botox in other US states?

Botox injector authority varies by state, licensed role and supervision arrangement, according to the state statutes, rules and boards checked October 17, 2026; there is no nationwide independent-injector permission for every RN or certificate holder. The state cards preserve each provision’s scope. They are a dated comparison, not personal legal clearance.

California’s Medical Board says physicians may inject Botox or direct registered nurses and physician assistants under their supervision, and unlicensed medical assistants may not. Texas treats nonsurgical cosmetic injections as the practice of medicine and describes physician delegation, orders and emergency availability. Washington distinguishes on-label physician-delegated treatment from off-label delegation. Its physician rule allows an offsite physician for the covered on-label arrangement if reachable by telephone and able to respond within thirty minutes; for medication not FDA-approved for that particular purpose, the physician must be onsite throughout. Do not change able to respond into a claim that a physician attends every treatment. Washington’s nursing statement separately requires an authorized practitioner’s prescription and competence. Colorado’s Rule 1.17 concerns delegation to unlicensed persons and expressly excludes nursing-board-regulated people, PAs and AAs. It cannot serve as the RN injection rule. Connecticut names physicians, PAs, APRNs and RNs in its medical-spa framework and requires an initial in-person assessment by a physician, PA or APRN. Other cards retain narrower nursing definitions or setting rules without expanding them into a complete authorization chart. The accessed Colorado consolidated version does not prove no later amendment exists, and the DC source is a June 2006 policy posted July 2012. Ask the relevant licensing board about the present arrangement before relying on a dated summary.

Safety and choosing care

How do I choose a Botox injector and check credentials?

Choose a Botox injector by checking the individual’s active license, actual training, prescribing arrangement and product source, as ASPS, AAD and CDC guidance checked October 17, 2026 advise. A credential is something to verify, not a ranking. A license alone does not authenticate the vial.

Ask who will perform the injection before booking, especially if the consultation uses a practice owner’s credentials while another person does the procedure. Record the exact license and named certification board for that individual. ASPS distinguishes plastic-surgery board certification from other certificates; a course certificate or society membership is not the same credential. State scope rules still apply. AAD recommends an in-office dermatologist be immediately available when staff administer injections; that is society safety guidance, distinct from a state’s legal minimum. AAD also advises against injections at nonmedical spas, parties, salons or homes, which should not be restated as an identical legal ban in every state. CDC recommends asking the provider to draw product from the labeled vial while you watch and says not to self-inject. Ask how the practice obtains the prescription product and records its name and lot. FDA’s 2024 counterfeit alert involved licensed and unlicensed individuals and said the reported events had not been linked to genuine FDA-approved AbbVie Botox. CDC’s closed 2024 investigation counted 17 cases and 13 hospitalizations across nine states, with no deaths. There was no denominator of all exposed people, so those counts are not a genuine-product complication rate. A historical counterfeit lot clue is not a complete authentication system. Expect a clear treatment record, a complication plan and a reachable clinician.

Safety and choosing care

What should I ask about Botox before and after photos?

Botox before and after photos are useful only when the product, areas, timing and other treatments are identified; the FDA labels checked October 17, 2026 evaluate specific areas and endpoints, not a generic facial transformation. Browse /photos/botox, then ask what the images actually document. A selected result does not establish your likelihood of the same change.

Compare a similar starting concern, with photographs at rest and during the same expression. Ask whether lighting, camera angle or facial movement changed. A smoother-looking face after combined filler, laser and toxin cannot isolate the effect of toxin. Cleveland Clinic explains that filler adds volume while toxin relaxes muscles, so a volume change needs its own explanation. Daxxify’s SAKURA research separates a week-four response from duration of none-or-mild lines and return to baseline. Those different assessments illustrate why the date and endpoint matter even when a caption says long lasting. At consultation, name the movement you want to retain and the concern you would accept leaving untreated. Ask the clinician to write the product, each area, its own units, any off-label purpose, anticipated limits and follow-up plan. Bring your medication list, allergy history and prior treatment record. The ASPS consultation checklist supports questions about the injector, expected results and complications; it is guidance without a measured patient denominator. If you remain uncertain, you can postpone the decision.

Go deeperBrowse Botox before and after photos